Sichuan, PRC – June 26, 2011 – China Health Resource, Inc. (OTCBB: CHRI) is a leading Chinese pharmaceutical company specializing in producing, processing, and commercializing Dahurian Angelica Root (DAR). Today, CHRI announced that the company has secured a large warehouse in Chuanshan District, in Suining City, in order to meet the growing market demands for increased DAR production. Covering 625 square meters, the new warehouse will ensure adequate market supply for storing high-quality DAR, which CHRI is widely known for.

CHRI has become a solid leader in DAR production in Sichuan Province, enticing many pharmaceutical companies to establish long-term agreements with the company for their ample supply of DAR. As a result, CHRI has secured two consecutive Letters of Intent to increase the purchase quantity of DAR with reputable leading enterprises within the pharmaceutical industry; Sichuan Zhiyuan Aquarious Pharmacy Co., Ltd and Chengdu Longevity Church Business Co., Ltd.

“The Company’s growth opportunities are tremendous, and we are pleased to expand our current facility to cater to the rising demand for DAR,” stated Jiayin Wang, CEO, CHRI.

The modern, upscale warehouse, selected by CHRI, covers 625 square meters and is located in Chuanshan District in Suining City. With the additional 520 square meters the company currently uses for DAR storage, capacity will reach 2,800 tons, valuing at 50 million yuan.

Additional information about China Health Resource, Inc. can be found by visiting http://ChinaHealthResource.com.

About CHRI

China Health Resource, Inc. (CHRI) engages in the development, manufacturing, processing, marketing, and sale of Dahurian Angelica Root (DAR) and related products in the People’s Republic of China. DAR, which is also known as “Bai Zhi” in Mandarin Chinese, is an herb that is employed as an ingredient in medicine, cosmetics and food, as well as used in TCM for the treatment of pain, swelling and pustule. The company’s DAR-related products include the Bailing Capsule, Yisheng Capsule, Kimchee-Mate and Fragrant Bag, all of which are sold through regional distributors. The company was founded in 2001 and is based in Suining.

SICHUAN, PRC- May 25, 2011 – China Health Resource, Inc. (OTCBB: CHRI), a producer and supplier of Traditional Chinese Medicine (TCM) products, announced on May 23, 2011, its financial results for the first quarter ending March 31, 2011. The report shows revenue of $4,378,000 and a net profit of $1,206,100, a record increase over previous year’s first quarter results.

“The first quarter earnings and revenue are a testament to our management team, dedicated staff, and loyal farmers,” said Jiayin Wang, CEO. “With a strong vision and an ambitious yet cautious strategy, CHRI is able to successfully supplement the health of the people while ensuring profitability of the Company. This has resulted in record levels for CHRI in 2011.”

CHRI reported a gross margin of over 34 percent as compared to 8.75 percent the preceding quarter. Net revenue is $859,600, with foreign currency gains were at $51,800.

The Company’s record revenue comes as a result of the numerous distribution and sales agreements negotiated in 2010 for an increase in the acquisition of the Dahurian Angelica Root (DAR), otherwise known as Bai Zhi in Mandarin. CHRI is currently the only GAP certified supplier and producer of this TCM drug in China and has already negotiated agreements for the introduction of a second TCM herb called Gastrodia, or Tianma in Mandarin.

“The Company has strived to provide the highest grade of TCM products and herbal remedies for our people and we will continue to do in 2011,” said Mr. Wang.

Additional information about China Health Resource, Inc. and the annual report can be found by visiting http://ChinaHealthResource.com under “Investor Relations”.

About CHRI

China Health Resource, Inc. engages in the development, manufacturing, processing, marketing and sale of Dahurian Angelica Root (DAR) and related products in the People’s Republic of China. DAR, which is also known as “Bai Zhi” in Mandarin Chinese, is an herb that is employed as an ingredient in medicine, cosmetics and food, as well as used in TCM for the treatment of pain, swelling and pustule. The company’s DAR-related products include the Bailing Capsule, Yisheng Capsule, Kimchee-Mate and Fragrant Bag, all of which are sold through regional distributors. The company was founded in 2001 and is based in Suining.

Certain statements found other than historical facts in this document regarding financial matters other than historical facts, and statements of our expectations, intentions, plans and beliefs, constitute “forward-looking statements” within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to certain events, risks and uncertainties that may be outside our control. The words “believe”, “expect”, “anticipate”, “optimistic”, “intend”, “will”, and similar expressions identify forward-looking statements. The company intends that such proclamations about future expectations, including future revenues and earnings, future business expansion plans, and all other forward-looking statements be subject to the safe harbors created thereby. Management retains broad discretion with regard to all future business operations of the Company. Since these statements involve risks and uncertainties and are subject to change at any time, the company’s actual results may differ materially from expected results. These and other risks and uncertainties related to our business are described in greater detail in our filings with the Commission. The foregoing information should be read in conjunction with these filings. We disclaim any intention or obligation to update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made.

Sichuan, PRC – May 11, 2011 – China Health Resource, Inc. (OTCBB: CHRI), today announced that the company has entered into an exclusive agreement with a leading producer of Gastrodia in Pingwu, Sichuan.  This agreement will give CHRI leverage in the Traditional Chinese Medicine (TCM) marketplace in China, as the main controlling distributor and supplier of Gastrodia (also known as Tianma), a traditional Chinese herb used to treat hypertension, improve circulation and resolve headaches.

Widely recognized for producing high-quality Angelica, CHRI is expanding its TCM offerings with a highly regarded and marketable TCM herb, commonly known as Tianma in China. Pure Gastrodia in Pingwu County of the Sichuan Province contains a high content of active ingredients, with low heavy metal content.  Free of pollution and boasting high quality, the demand in the market for pure Gastrodia surpasses the supply in Pingwu
County.

“Although Pingwu County is well-known for Gastrodia, the company is a rather small operation,” stated Jiayin Wang, CEO, China Health Resource, Inc.  “As our company is widely known for producing high-quality Angelica, securing this contract makes for a solid combination between a large enterprise and a high-quality product.  With the high value of Gastrodia, we hope to broaden our product line, resulting in increased profits.”

Gastrodia currently retails for about 250~1,000 yuan/kg (US$38~150/kg) and is considered one of China’s highest priced TCM drugs available in the market. This exclusive arrangement for the supply of Gastrodia is expected to generate an estimated 120 million yuan (US$18 million) of revenue each year for CHRI.

Additional information about China Health Resource, Inc. and the Chinese herbal medicine, Gastrodia, can be found by visiting http://ChinaHealthResource.com.

About CHRI

China Health Resource, Inc. engages in the development, manufacturing, processing,
marketing and sale of Dahurian Angelica Root (DAR) and related products in the
People’s Republic of China.  DAR, which is also known as “Bai Zhi” in Mandarin Chinese, is an herb that is employed as an ingredient in medicine, cosmetics and food, as well as used in TCM for the treatment of pain, swelling and pustule. The company’s DAR-related products include the Bailing Capsule, Yisheng Capsule, Kimchee-Mate and Fragrant Bag, all of which are sold through regional distributors. The company was founded in 2001 and is based in Suining.

Certain statements found other than historical facts in this document regarding financial matters other than historical facts, and statements of our expectations, intentions, plans and beliefs, constitute “forward-looking statements” within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to certain events, risks and uncertainties that may be outside our control. The words “believe”, “expect”, “anticipate”, “optimistic”, “intend”, “will”, and similar expressions identify forward-looking statements. The company intends that such proclamations about future expectations, including future revenues and earnings, future business expansion plans, and all other forward-looking statements be subject to the safe harbors created thereby. Management retains broad discretion with regard to all future business operations of the Company.  Since these statements involve risks and uncertainties and are subject to change at any time, the company’s actual results may differ materially from expected results. These and other risks and uncertainties related to our business are described in greater detail in our filings with the Commission.  The foregoing information should be read in conjunction with these filings. We disclaim any intention or obligation to update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made.

Earnings Release

China Health Resource, Inc. Announces a Profitable Year Under New Management
China Health Resource, Inc. achieves record revenues of over $10 million,
earnings per share of US$0.0183

SICHUAN, PRC- April 26, 2011 – China Health Resource, Inc. (OTCBB: CHRI) announced on April 11, 2011, its financial results for fiscal year ending December 31, 2010. The report reflects 2010’s annual revenue of US$10,282,207, an increase of 134 percent from the
previous year.

“We are pleased to announce a great year (2010) for the Company. Our continuous efforts to support the consumer with a better, healthier lifestyle choice, and diligent work in
providing only the best quality herbs for the people of China has resulted in an increase of 134 percent compared to year-end 2009,” said Jiayin Wang, CEO.

CHRI’s net income of US$2,785,881 was a result from increased sales, lower SG&A expense, and a foreign currency translation gain between the RMB and USD of US$78,595.

CHRI has mapped out its plans for 2011, placing a strong emphasis on sales and increasing distribution for current and new additions to its line of Traditional Chinese Medicine
(“TCM”). The Company plans on leveraging government programs in the agricultural sector, driven by substantial market demand, to increase margins for its line of TCM drugs.

“We ended 2010 with record revenues and robust demand for Sichuan Angelica products across all geographies and channels in China,” said Mr Wang. “In 2011, we look
forward to continued growth as we ramp our sales and distribution strategies, and
expand our product line to new TCM drugs.”

Additional information about China Health Resource, Inc. and the annual report can be
found by visiting http://ChinaHealthResource.com under “Investor Relations”.

About CHRI

China Health Resource, Inc. engages in the development, manufacturing, processing,
marketing and sale of Dahurian Angelica Root (DAR) and related products in the
People’s Republic of China.  DAR, which is also known as “Bai Zhi” in Mandarin Chinese, is an herb that is employed as an ingredient in medicine, cosmetics and food, as well as used in TCM for the treatment of pain, swelling and pustule. The company’s DAR-related products include the Bailing Capsule, Yisheng Capsule, Kimchee-Mate and Fragrant Bag, all of which are sold through regional distributors. The company was founded in 2001 and is based in Suining.

Certain statements found other than historical facts in this document regarding financial matters other than historical facts, and statements of our expectations, intentions, plans and beliefs, constitute “forward-looking statements” within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to certain events, risks and uncertainties that may be outside our control. The words “believe”, “expect”, “anticipate”, “optimistic”, “intend”, “will”, and similar expressions identify forward-looking statements. The company intends that such proclamations about future expectations, including future revenues and earnings, future business expansion plans, and all other forward-looking statements be subject to the safe harbors created thereby. Management retains broad discretion with regard to all future business operations of the Company.  Since these statements involve risks and uncertainties and are subject to change at any time, the company’s actual results may differ materially from expected results. These and other risks and uncertainties related to our business are described in greater detail in our filings with the Commission.  The foregoing information should be read in conjunction with these filings. We disclaim any intention or obligation to update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made.

Complied in Chengdu, data to help with planting and pricing.

A new index of Chinese herbal medicines published in Chengdu, capital of Sichuan province, on April 16 will help both the government and businesses in the field understand trends and promote further development of the industry, said Zhang Jinquan, deputy director of Chengdu Commerce Bureau.

“The index will become a weather vane in the country’s herbal medicine market,” Zhang said.

Authorized by the Ministry of Commerce, the Chengdu Index carries prices and purchase data on medicines reflecting the overall commerce in traditional Chinese medicines.

The price list, which includes 1,275 kinds of medicines, is published each week, according to Zhang.

Read full article.

Governance

SEC Filings

All quarterly and annual filings are available from this website with a direct link to all original filings on the SEC.gov website. Please click on filing descriptions to view all SEC filings.

Recognized for its high-quality Angelica in the native market of Sichuan, CHRI has signed a Letter of Intent with five villages to ensure the company’s Angelica production remains superior in the Chinese medicine field. Known for their high-quality Angelica production, the five villages include Chuanlingshi Village, Zhongji Village of Yongxing Town, Shunhe Village of Xinqiao Town in Chuanshan District, Guojunba Village of Jinqiao Township in Pengxi County, and Fujiang Village of Huima Town in Daying County.

“Producing high-quality raw material in the Chinese medicine field is crucial,” stated Jiayin Wang, CEO, CHRI.  “With the global climate and regional growing environment deteriorating, fierce market competition has intensified amongst many pharmaceutical factories.  CHRI has established a solid reputation to meet demand for the highest-quality Angelica, and we will continue to explore new means to ensure we maintain this distinguished reputation.”

With this Letter of Intent, the quantity for CHRI will be increased to 4,000 tons, making up 80% of the entire amount purchased in 2010, and it is estimated the sales, as a whole, will reach 72 million yuan (approximately US$10.9 million).  In addition, with the Letter of Intent signed with both Sichuan Zhiyuan Aquarious Pharmacy Co., Ltd and Chengdu Longevity Church Business Co., Ltd, the Company estimates that it will purchase Angelica in amounts that far exceed the levels established in previous years.

Further details are currently being negotiated between the two companies.

Additional information about China Health Resource, Inc. and the five villages can be found by visiting http://ChinaHealthResource.com.

About CHRI

China Health Resource, Inc. engages in the development, manufacturing, processing, marketing and sale of Dahurian Angelica Root (DAR) and related products in the
People’s Republic of China.  DAR, which is also known as “Bai Zhi” in Mandarin Chinese, is an herb that is employed as an ingredient in medicine, cosmetics and food, as well as used in TCM for the treatment of pain, swelling and pustule. The company’s DAR-related products include the Bailing Capsule, Yisheng Capsule, Kimchee-Mate and Fragrant Bag, all of which are sold through regional distributors. The company was founded in 2001 and is based in Suining.

Certain statements found other than historical facts in this document regarding financial matters other than historical facts, and statements of our expectations, intentions, plans and beliefs, constitute “forward-looking statements” within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to certain events, risks and uncertainties that may be outside our control. The words “believe”, “expect”, “anticipate”, “optimistic”, “intend”, “will”, and similar expressions identify forward-looking statements. The company intends that such proclamations about future expectations, including future revenues and earnings, future business expansion plans, and all other forward-looking statements be subject to the safe harbors created thereby. Management retains broad discretion with regard to all future business operations of the Company.  Since these statements involve risks and uncertainties and are subject to change at any time, the company’s actual results may differ materially from expected results. These and other risks and uncertainties related to our business are described in greater detail in our filings with the Commission.  The foregoing information should be read in conjunction with these filings. We disclaim any intention or obligation to update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made.